DeFinium Therapeutics Inc (DFTX) Stock Price, Quote & News

Company Profile

Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mi...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 220 6633

Website: definiumtx.com

Address:

One World Trade Center, Suite 8500, New York, United States

BullsVSBearsVSYoMomma Feb. 22 at 8:20 PM

$DFTX That's a besutiful trajectory

0 · Reply

IBSpazzin Feb. 22 at 3:45 PM

$DFTX are we looking for anything major from ER?

0 · Reply

Chukt22 Feb. 21 at 2:49 AM

This needs to be understood by more…… so I’m Tagging my 4 largest spec holdings that I am still, despite a very bearish macro view, insanely bullish on, that I believe are highly politically and macro secular, undervalued, and will be this years big winners regardless. $LUNR $DFTX $RKLB room for one more, but those are the only 3 I have more than 10% in. (in order of conviction)

1 · Reply

BullsVSBearsVSYoMomma Feb. 20 at 8:59 PM

$DFTX Bullish sideways consolidation. Get ready for a pump past $20 when we break out of this

0 · Reply

zcurrency Feb. 20 at 4:17 AM

$DFTX

0 · Reply

Sailingsoon Feb. 19 at 9:08 PM

$DFTX

0 · Reply

MichaelNaussCMT Feb. 19 at 1:01 AM

$DFTX yes

0 · Reply

jdawgger Feb. 18 at 11:57 PM

$DFTX Fda dropping 2 trial requirement for new drugs..... is this huge?

1 · Reply

hemlock17 Feb. 18 at 5:16 PM

$DFTX

0 · Reply

BobbyCucumber Feb. 18 at 5:12 PM

$DFTX ...goral, hello.....hello.....HELLO???!!...

1 · Reply

Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026

Feb 2, 2026, 4:00 PM EST - 20 days ago

Definium Therapeutics Announces New Employee Inducement Grants

Jan 29, 2026, 7:00 AM EST - 25 days ago

Definium Therapeutics Appoints Roger Adsett to Board of Directors

Jan 20, 2026, 7:00 AM EST - 4 weeks ago

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

Jan 14, 2026, 7:16 PM EST - 5 weeks ago

Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MMED

Jan 13, 2026, 7:00 AM EST - 5 weeks ago

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Jan 12, 2026, 7:00 AM EST - 6 weeks ago

MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026

Dec 18, 2025, 7:01 AM EST - 2 months ago

MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 4:01 PM EST - 2 months ago

MindMed Announces New Employee Inducement Grant

Dec 1, 2025, 4:01 PM EST - 2 months ago

MindMed Announces New Employee Inducement Grants

Nov 6, 2025, 9:46 PM EST - 3 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:01 PM EST - 3 months ago

MindMed Reports Q3 2025 Financial Results and Business Updates

Nov 5, 2025, 7:01 AM EST - 3 months ago

MindMed to Participate in Upcoming Investor Conferences

Nov 3, 2025, 7:01 AM EST - 4 months ago

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Oct 30, 2025, 4:01 PM EDT - 4 months ago

MindMed to Report Q3 2025 Financial Results on November 6, 2025

Oct 29, 2025, 10:14 PM EDT - 4 months ago

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Oct 29, 2025, 4:01 PM EDT - 4 months ago

Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

Oct 14, 2025, 12:28 PM EDT - 4 months ago

MindMed Nears Pivotal Year: Strong Fundamentals Make It A Buy

Oct 13, 2025, 2:54 PM EDT - 4 months ago

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Sep 19, 2025, 7:00 AM EDT - 5 months ago

New MindMed Retrospective Study Presented at Psych Congress 2025 Reveals High Rates of Suicidal Ideation (SI) in Adults with Generalized Anxiety Disorder (GAD)

Sep 4, 2025, 11:05 AM EDT - 6 months ago

Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the Dose-Dependent Efficacy of MM120 (Lysergide D-Tartrate, LSD) in Generalized Anxiety Disorder (GAD)

Aug 28, 2025, 7:00 AM EDT - 6 months ago

MindMed to Participate in September Investor Conferences

Jul 31, 2025, 9:48 PM EDT - 7 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:01 PM EDT - 7 months ago

MindMed Reports Q2 2025 Financial Results and Business Updates

Jul 24, 2025, 7:00 AM EDT - 7 months ago

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

May 28, 2025, 7:00 AM EDT - 9 months ago

MindMed to Participate in June Investor Conferences

May 27, 2025, 7:00 AM EDT - 9 months ago

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

May 13, 2025, 7:00 AM EDT - 10 months ago

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 8, 2025, 9:55 AM EDT - 10 months ago

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:00 AM EDT - 10 months ago

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

Apr 24, 2025, 7:00 AM EDT - 10 months ago

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 15, 2025, 7:00 AM EDT - 11 months ago

MindMed Announces First Patient Dosed in Phase 3 Emerge Study of MM120 in Major Depressive Disorder (MDD)

Mar 17, 2025, 7:00 AM EDT - 1 year ago

MindMed Appoints Matt Wiley as Chief Commercial Officer

Mar 6, 2025, 12:10 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 7:00 AM EST - 1 year ago

MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates

Mar 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at Leerink's Global Healthcare Conference 2025

Feb 20, 2025, 7:00 AM EST - 1 year ago

MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

MindMed to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Panorama, the Second Pivotal Phase 3 Study of MM120 in Generalized Anxiety Disorder

Dec 19, 2024, 7:00 AM EST - 1 year ago

MindMed to Be Added to the Nasdaq Biotechnology Index

Dec 16, 2024, 7:00 AM EST - 1 year ago

MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD)

Dec 11, 2024, 7:00 AM EST - 1 year ago

MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress

Dec 5, 2024, 7:00 AM EST - 1 year ago

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Dec 3, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy

Nov 18, 2024, 7:00 AM EST - 1 year ago

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

Nov 10, 2024, 9:55 AM EST - 1 year ago

Mind Medicine: No News = Good News

Nov 7, 2024, 8:06 PM EST - 1 year ago

Mind Medicine (MindMed) Inc. (MNMD) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

Nov 4, 2024, 4:04 PM EST - 1 year ago

Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate

Oct 24, 2024, 7:00 AM EDT - 1 year ago

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

BullsVSBearsVSYoMomma Feb. 22 at 8:20 PM

$DFTX That's a besutiful trajectory

0 · Reply

IBSpazzin Feb. 22 at 3:45 PM

$DFTX are we looking for anything major from ER?

0 · Reply

Chukt22 Feb. 21 at 2:49 AM

1 · Reply

BullsVSBearsVSYoMomma Feb. 20 at 8:59 PM

$DFTX Bullish sideways consolidation. Get ready for a pump past $20 when we break out of this

0 · Reply

zcurrency Feb. 20 at 4:17 AM

$DFTX

0 · Reply

Sailingsoon Feb. 19 at 9:08 PM

$DFTX

0 · Reply

MichaelNaussCMT Feb. 19 at 1:01 AM

$DFTX yes

0 · Reply

jdawgger Feb. 18 at 11:57 PM

$DFTX Fda dropping 2 trial requirement for new drugs..... is this huge?

1 · Reply

hemlock17 Feb. 18 at 5:16 PM

$DFTX

0 · Reply

BobbyCucumber Feb. 18 at 5:12 PM

$DFTX ...goral, hello.....hello.....HELLO???!!...

1 · Reply

dlawler_99 Feb. 18 at 3:30 PM

$DFTX

0 · Reply

zcurrency Feb. 18 at 3:29 PM

$DFTX patiently waiting for gorals next price update 💰

0 · Reply

Thebullrun Feb. 18 at 3:10 PM

$DFTX $BETRF BETRF is the only other LSD related drug being developed with no psychoactive side effects and no need to go clinic. This is great news.

0 · Reply

Rx2 Feb. 18 at 1:35 PM

$CMPS anyone else a little baffled at the difference in market cap vs $DFTX? CMPS is literally filing for approval this yr with 2 positive pivotal ph3 data in hand, solid IP, and enough cash to get to launch. Seems too easy to just buy & hold here

2 · Reply

JamesBenz401 Feb. 17 at 11:00 PM

$DFTX when is the move coming???? $4 average !!

0 · Reply

directorwalsh Feb. 17 at 6:42 PM

$DFTX Avoro took 5% stake in Q4

2 · Reply

grumpygoose Feb. 17 at 6:27 PM

$DFTX @goral17 Bend over Goral, it's time.

1 · Reply

BobbyCucumber Feb. 17 at 6:13 PM

$DFTX My 2000 CMPS shares looking UNREAL TODAY!!! Great news for the whole sector, fantastic Phase 3 results the catalyst we needed, gains look like they're holding pretty good also.

0 · Reply

Defen Feb. 17 at 2:36 PM

$DFTX nice move today been a few bad days

0 · Reply

Rocketzz Feb. 17 at 2:52 AM

$ATAI $CMPS $DFTX Whole sector will move on $CMPS results tomorrow

0 · Reply

Sailingsoon Feb. 16 at 10:03 AM

$DFTX Green in Europe

0 · Reply

Framingtheworld Feb. 16 at 3:06 AM

$ATAI $HELP $DFTX lets goooooo

0 · Reply

Market Cap	1.69B
Revenue (ttm)	0.00
Net Income (ttm)	-108.68M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.31

Volume	1,011,000
Avg Vol	1,959,926
Day's Range	N/A - N/A
Shares Out	98.51M
Stochastic %K	69%
Beta	2.57
Analysts	Strong Sell
Price Target	$29.46